

(FINAL/APPROVED)

VIRGINIA BOARD OF PHARMACY

**PUBLIC HEARINGS FOR PHARMACEUTICAL PROCESSOR REGULATIONS AND TO
SCHEDULE CERTAIN CHEMICALS IN SCHEDULE I**

March 26, 2019
Commonwealth Conference Center
Second Floor
Board Room 2

Department of Health Professions
Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233-1463

CALL TO ORDER: The public hearings were called to order at 9:10 a.m.

PRESIDING: Rafael Saenz, Chairman

MEMBERS PRESENT: Glenn L. Bolyard, Jr.
Melvin L. Boone, Sr.
Ryan K. Logan
Cheryl H. Nelson
Kristopher S. Ratliff
Patricia Richards-Spruill
Rebecca Thornbury
Cynthia Warriner

MEMBER ABSENT: James L. Jenkins, Jr.

STAFF PRESENT: Caroline D. Juran, Executive Director
J. Samuel Johnson, Jr., Deputy Executive Director
Beth O'Halloran, Deputy Executive Director
Ellen Shinaberry, Deputy Executive Director
Elaine J. Yeatts, Senior Policy Analyst, DHP
James Rutkowski, Assistant Attorney General
David E. Brown, DC, Director, DHP
Barbara Allison-Bryan, MD, Deputy Director, DHP
Kiara Christian, Executive Assistant

CALL FOR PUBLIC COMMENT: Mr. Saenz called for comment to consider placement of the following chemicals into Schedule I:

A powerful synthetic opioid:

- 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropyl-benzamide (other name: Isopropyl U-47700)

Research chemicals:

- alpha-pyrrolidinoisohexiophenone (other name: alpha-

PiHP)

- 1-[1-(3-hydroxyphenyl)cyclohexyl]piperidine (other name: 3-hydroxy PCP)

If approved by the Board of Pharmacy, the placement of these substances in Schedule I shall go into effect 30 days following publication of the proposed regulation and remain in effect for a period of 18 months. The chemicals will then be de-scheduled unless a general law is passed by the General Assembly placing the chemicals into Schedule I.

PUBLIC COMMENT:

Scott May, Chemistry Program Manager with the Department of Forensic Science provided information on the 3 chemicals the department has identified for the Board's consideration to place into Schedule I.

No other comment on this subject was provided.

CALL FOR PUBLIC COMMENT:

Mr. Saenz then call for public comment on the proposed regulations for pharmaceutical processors. Copies of the proposed regulations were provided to the board members and on the back table for the public.

PUBLIC COMMENT:

Caley Crawford, with Virginia Medical Cannabis Coalition which represents the five pharmaceutical processors, offered comment that their mission is to ensure all laws and regulations are aligned with the goal of patient safety. Ms. Crawford commended the board and added that she is pleased with the passage of SB 1557 and SB 1719 that increases access, formulations, and labeling, and offered to serve as a resource to the board.

Aaron Lopez, representing Dalitso, made comment asking the board to remain vigilant in the unregulated sales of over-the-counter CBD products. He offered that the unregulated sale of CBD is confusing to the public and that the CBD suppliers are not being held accountable to the same standards as the pharmaceutical processors.

Jean Michelle Pedini, Executive Director of Virginia NORML thanked the board for allowing Virginians to access CBD. She expressed concern over unregulated products, patient safety, access, and affordability.

Dylan Bishop, Virginia Cannabis Association, offered support to the board.

ADJOURN:


The public hearing adjourned at 9:25am.



Rafael Saenz, Chairman

6-5-19

Date



Caroline D. Juran, Executive Director

6/5/19

Date